Traditional Chinese medicine composition for lung tumor treatment, preparation method and application
Through the specific proportion of traditional Chinese medicine compositions and preparation methods, combined with the combination of cyclophosphamide, the inhibitory effect and immune function of lung tumors are significantly improved, and the problem of poor treatment effect of lung tumors in the prior art has been solved, and the Effective prevention and immunity improvement for tumor growth.
Patent Information
- Application Number
- CN202411323157.8
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-10-24
- Publication Date
- 2024-12-03
- Estimated Expiration
- Not applicable · inactive patent
AI Technical Summary
The existing traditional Chinese medicine compositions for the treatment of lung tumors have insufficient inhibitory effect on lung tumor growth, and the effect of improving immune function needs to be further improved.
Using a composition composed of traditional Chinese medicines such as wild chrysanthemum, honeysuckle, mint, poria, atractylodes, cinnamon, astragalus, Ganoderma lucidum, chuanxiong, scented tangerine, licorice, etc., it is made into a variety of dosage forms through specific ratios and preparation methods, including injections and honey. Pill refining, etc., combined with cyclophosphamide combined to enhance the therapeutic effect.
It significantly improved the preventive effect on tumor growth in A-549 tumor-bearing nude mice, enhanced the body's immunity, and increased the number of white blood cells, neutrophils and lymphocytes after use alone or in combination with cyclophosphamide, and increased the immunity Function.
Smart Images

Figure FT_1 
Figure FT_2 
Figure FT_3
Abstract
Description
Technical Field
[0001] The present invention relates to the technical field of traditional Chinese medicines, and in particular to a traditional Chinese medicine composition for treating lung tumors, a preparation method and use thereof. Background Art
[0002] Cancer in the human body is basically caused by a decline in the body's immunity, which leads to an imbalance in immune function and uncontrolled growth of cancer cells.
[0003] Immunotherapy is a new treatment method for cancer in recent years. Western medicine immunotherapy is usually combined with chemotherapy and radiotherapy, which has certain therapeutic effects, but has side effects and drug resistance.
[0004] In this regard, a Chinese invention patent with publication number CN108567820B has developed a traditional Chinese medicine composition for the treatment of lung tumors. It solves this technical problem by combining thirteen herbs. However, the inhibitory effect of the traditional Chinese medicine composition on the growth of lung tumors needs to be improved. Summary of the invention
[0005] The purpose of the present invention is to provide a Chinese medicine composition for the treatment of lung tumors, a preparation method and use thereof, in view of the defects and shortcomings of the prior art, which has the advantage of having a significant preventive effect on tumor growth.
[0006] To achieve the above purpose, the technical solution adopted by the present invention is: a traditional Chinese medicine composition for treating lung tumors, which is made of the following raw materials in weight ratio: 5%-15% of wild chrysanthemum, 2%-12% of honeysuckle, 5%-15% of mint, 5%-15% of poria, 10%-20% of atractylodes, 0.5%-3% of cinnamon, 0.5%-3% of cloves, 3%-12% of astragalus, 5%-15% of ganoderma lucidum, 10%-20% of chuanxiong, 5%-12% of costusroot, and 2%-10% of liquorice.
[0007] The present invention further provides that the traditional Chinese medicine composition for the treatment of lung tumors is made of the following raw materials in weight ratio: 5%-10% wild chrysanthemum, 3%-8% honeysuckle, 5%-10% mint, 5%-10% poria, 12%-20% atractylodes, 0.5%-3% cinnamon, 0.5%-3% clove, 5%-10% astragalus, 5%-10% ganoderma lucidum, 11%-15% ligusticum, 8%-12% costusroot, and 3%-8% licorice.
[0008] The present invention further provides that the traditional Chinese medicine composition for the treatment of lung tumors is made of the following raw materials in weight ratio: 6%-9% wild chrysanthemum, 3%-6% honeysuckle, 6%-9% mint, 6%-9% poria, 15%-18% atractylodes, 1%-3% cinnamon, 0.5%-1.5% clove, 6%-10% astragalus, 6%-10% ganoderma lucidum, 12%-15% ligusticum, 8%-11% costusroot, and 3%-6% licorice.
[0009] The present invention further provides that the dosage form of the Chinese medicine composition for treating lung tumors is: injection, honey-refined pills, hydrated pills, capsules, tablets, pellets, powders, oral liquid medicines, gels, extracts or films.
[0010] To achieve the above object, another technical solution adopted by the present invention is: a method for preparing a Chinese medicine composition for treating lung tumors, the preparation method comprising the following steps:
[0011] Step (1) weighing each Chinese medicinal ingredient according to the weight ratio, crushing them to a particle size of 10-100 mesh, sieving them, and mixing them evenly;
[0012] Step (2) preparing an ethanol solution with a concentration of 40%-95% for standby use; soaking the mixed Chinese medicine with the prepared ethanol solution with a concentration of 40%-95% for 10-48 hours, adding the soaked Chinese medicine mixture into a percolation bucket in batches, and lightly pressing and flattening;
[0013] Step (3) adding the prepared 40%-95% ethanol solution to the percolation barrel in step (2) until it exceeds the surface of the medicinal material by 1-2 cm, and after soaking for a preset time, percolating the remaining ethanol, and retaining the medicinal residue for later use; the obtained alcohol solution is concentrated under reduced pressure, and dried to obtain the Chinese medicine composite powder A;
[0014] Step (4) adding 2-10 times the amount of water to the medicinal residue, decocting and extracting for 0.5-2h, centrifuging and filtering, decompressing and concentrating the medicinal solution and drying to obtain a Chinese medicine composite powder B, and uniformly mixing the Chinese medicine composite powder A and the Chinese medicine composite powder B to obtain a Chinese medicine composition.
[0015] The present invention further provides that in step (1), various medicinal materials are crushed to a particle size of 20-40 mesh; and the concentration of the prepared ethanol in steps (2) and (3) is 60%-80%.
[0016] The present invention is further arranged that in the step (2), the uniformly mixed traditional Chinese medicine is soaked for 18-30 hours; and in the step (3), the soaking time is 2-48 hours.
[0017] To achieve the above object, another technical solution adopted by the present invention is: a method for preparing a Chinese medicine composition for treating lung tumors, the preparation method comprising the following steps:
[0018] Step (1) according to the weight ratio, weigh Chuanxiong, Atractylodes, Aucklandia, Clove, Cinnamon, and Menthol, add appropriate amount of water to extract volatile oil, add cyclodextrin for inclusion, filter the decoction and collect it in another device as the remaining medicinal liquid for standby use;
[0019] Step (2) boiling the residue obtained after the volatile oil is extracted and the tuckahoe, astragalus, wild chrysanthemum, ganoderma lucidum, honeysuckle and liquorice weighed according to the weight ratio in water, filtering the liquid medicine, and combining the filtered liquid medicine with the remaining liquid medicine obtained after the volatile oil is extracted to obtain a mixed Chinese medicine liquid medicine;
[0020] Step (3) concentrating the obtained Chinese medicine mixed liquid into a clear paste by water bath, precipitating with alcohol, and adding ethanol to make the alcohol content reach 50%-80% to obtain a Chinese medicine mixed alcohol liquid;
[0021] Step (4) concentrates the Chinese medicine mixed alcohol solution under reduced pressure, and after drying, adds volatile oil cyclodextrin inclusion compound to prepare a Chinese medicine composition.
[0022] The present invention further provides that in the step (1), the amount of volatile oil extraction solvent used is 4-15 times the amount of water of the medicinal material, and the extraction time is 2-12 hours; the obtained volatile oil is subjected to cyclodextrin inclusion at below 40 degrees Celsius, and the inclusion time is 1-10 hours.
[0023] To achieve the above object, another technical solution adopted by the present invention is: a use of a Chinese medicine composition, wherein the Chinese medicine composition is used in combination with cyclophosphamide for the treatment of lung tumors.
[0024] After adopting the above technical solution, the beneficial effects of the present invention are:
[0025] 1. In the present invention, Ganoderma lucidum nourishes the five internal organs, invigorates the spleen and replenishes qi, and improves the body's immunity; Astragalus invigorates the spleen and replenishes the lungs, invigorates qi and raises yang, and improves the body's immunity; Ganoderma lucidum and Astragalus can inhibit the growth of tumor telomerase; Atractylodes lancea, Poria cocos, and Licorice invigorate the spleen and eliminate dampness; Cinnamon bark, Aucklandia lappa, and Clove are pungent and warm, regulating qi, warming the middle, dispersing cold and relieving pain; Honeysuckle clears heat and detoxifies; Wild chrysanthemum clears the liver, improves eyesight and detoxifies; Mint is pungent and cool and detoxifies, soothes the liver and relieves depression; Chuanxiong regulates qi, promotes blood circulation and relieves pain. This prescription uses Ganoderma lucidum and Astragalus invigorates the spleen and replenishes qi, invigorates the five internal organs, strengthens the body and consolidates the foundation, and resists tumors as the main drugs, Atractylodes lancea, Poria cocos, Licorice invigorates the spleen and eliminates dampness, Cinnamon bark, Aucklandia lappa, and Clove are ministerial drugs, regulating qi, warming the middle, dispersing cold and relieving pain, Wild chrysanthemum and honeysuckle clear heat and detoxify as adjuvant drugs, Chuanxiong and Mint are messenger drugs for clearing liver, promoting blood circulation and relieving pain.
[0026] 2. The Chinese medicine composition of the present invention has a significant preventive effect on tumor growth in A-549 tumor-bearing nude mice.
[0027] 3. The Chinese medicine composition of the present invention can increase the number of white blood cells, neutrophils, lymphocytes and monocytes when used alone or in combination with cyclophosphamide. BRIEF DESCRIPTION OF THE DRAWINGS
[0028] In order to more clearly illustrate the embodiments of the invention or the technical solutions in the prior art, the drawings required for use in the embodiments or the description of the prior art will be briefly introduced below. Obviously, the drawings described below are only some embodiments of the present invention. For ordinary technicians in this field, other drawings can be obtained based on these drawings without paying creative labor.
[0029] Figure 1 It is the tumor growth curve;
[0030] Figure 2 It is the tumor growth curve;
[0031] Figure 3 It is the weight change curve;
[0032] Figure 4 It is the curve of weight growth rate;
[0033] Figure 5 These are photos of tumor tissues in each group. DETAILED DESCRIPTION
[0034] The present invention is further described in detail below in conjunction with the accompanying drawings.
[0035] This specific embodiment is only an explanation of the present invention, and it is not a limitation of the present invention. After reading this specification, those skilled in the art can make non-creative modifications to this embodiment as needed, but as long as it is within the scope of the claims of the present invention, it is protected by the patent law.
[0036] Example 1
[0037] A traditional Chinese medicine composition for treating lung tumors is prepared from the following raw materials in the following weight ratios: 9% chrysanthemum, 5% honeysuckle, 7% mint, 8% tuckahoe, 16% atractylodes, 2% cinnamon, 1% clove, 10% astragalus, 12% ganoderma lucidum, 13% chuanxiong, 9% costusroot, and 8% liquorice.
[0038] The preparation method of the Chinese medicine composition for treating lung tumors comprises: weighing each Chinese medicine raw material according to the above weight ratio, crushing them to a particle size of 20 meshes, and then mixing them evenly; preparing an ethanol solution with a concentration of 70% for standby use; soaking the mixed Chinese medicine for at least 24 hours with the prepared ethanol solution with a concentration of 70%, adding the soaked Chinese medicine mixture into a percolation bucket in batches, and lightly pressing and flattening; dissolving the prepared ethanol solution with a concentration of 70% to a level of 1-2 cm above the surface of the medicinal material, and soaking for 18- After 30 hours (optimally 20 hours of soaking), the remaining ethanol solution is added to the percolation barrel, added to the percolation, and the drug residue is retained for standby use; the obtained alcohol solution is concentrated under reduced pressure, and dried to obtain the soaked Chinese medicine composite powder A; the drug residue is added with 2-10 times (optimally 8 times) of water as much as the drug residue, decocted and extracted for 0.5-2 hours (optimally 1 hour), centrifuged, the drug solution is concentrated under reduced pressure and dried to obtain the Chinese medicine composite powder B, and the Chinese medicine composite powder A and the Chinese medicine composite powder B are evenly mixed to obtain a Chinese medicine composition.
[0039] Example 2
[0040] A traditional Chinese medicine composition for treating lung tumors is prepared from the following raw materials in weight proportion: 8% chrysanthemum, 7% honeysuckle, 7% mint, 9% tuckahoe, 15% atractylodes, 2% cinnamon, 2% clove, 11% astragalus, 10% ganoderma lucidum, 14% chuanxiong, 10% costusroot, and 5% liquorice.
[0041] The preparation method of the traditional Chinese medicine composition comprises: weighing chuanxiong, atractylodes, costusroot, clove, cinnamon bark and mint according to the mass ratio, adding an appropriate amount of volatile oil extraction solvent to extract volatile oil, wherein the amount of volatile oil extraction solvent used is 6 times the amount of water of the medicinal materials, and the extraction time is 2-12 hours (optimally 10 hours); after the volatile oil is extracted, cyclodextrin inclusion is carried out at a temperature below 40 DEG C, and the inclusion time is 6 hours; the water decoction is filtered and collected in another device as a filtrate for standby use; mixing the drug residue obtained after the volatile oil extraction with tuckahoe, astragalus, wild chrysanthemum, ganoderma lucidum, honeysuckle and liquorice weighed according to the weight ratio, and adding 10-15 times (optimally 10 hours) of cyclodextrin; and mixing the volatile oil with the volatile oil extracting solvent. The method comprises the following steps: decocting the medicinal liquid obtained by decocting the medicinal material with water (12 times the amount of the medicinal material) for 2-5 times (preferably 3 times), each time for 1-2 hours (preferably 1.5 hours); filtering the medicinal liquid obtained by decocting, combining the filtered medicinal liquid with the filtrate obtained after extracting the volatile oil to obtain a Chinese medicine mixed medicinal liquid; concentrating the obtained Chinese medicine mixed medicinal liquid by water bath to a clear paste with a relative density of 1.06-1.08, adding ethanol to make the alcohol content reach 60%, and standing for more than 12 hours (preferably 48 hours) to obtain a Chinese medicine mixed alcohol liquid; concentrating the Chinese medicine mixed alcohol liquid under reduced pressure, drying, and adding a volatile oil cyclodextrin inclusion compound to obtain a Chinese medicine composition.
[0042] Example 3
[0043] A Chinese medicine composition for treating lung tumors, which is prepared from the following raw materials in weight ratio: 7% wild chrysanthemum, 6% honeysuckle, 8% mint, 11% tuckahoe, 17% atractylodes, 1.5% cinnamon, 0.5% clove, 9% astragalus, 9% ganoderma lucidum, 16% chuanxiong, 9% costusroot, and 6% liquorice 。
[0044] The preparation method of the Chinese medicine composition comprises: weighing each Chinese medicine raw material according to the weight ratio; preparing an ethanol solution with a concentration of 60% for standby use; adding 6 times the prepared ethanol solution to the uniformly mixed Chinese medicine, heating and refluxing extraction for 2 times (heating to slight boiling for refluxing extraction), each time for 1-2 hours (optimally 1.5 hours), combining the 2 extracts, recovering ethanol under reduced pressure, and concentrating and drying to obtain the Chinese medicine composition.
[0045] Example 4
[0046] A traditional Chinese medicine composition for treating lung tumors is prepared from the following raw materials in weight proportion: 9% wild chrysanthemum, 7% honeysuckle, 7% mint, 8% tuckahoe, 13% atractylodes, 2% cinnamon, 1% clove, 10% astragalus, 15% ganoderma lucidum, 13% chuanxiong, 7% costusroot, and 8% liquorice.
[0047] The preparation method of the Chinese medicine composition comprises: weighing each Chinese medicine raw material according to the above weight ratio, crushing them to a particle size of 30 meshes respectively, and then mixing them evenly after sieving; preparing an ethanol solution with a concentration of 65% for standby; soaking the evenly mixed Chinese medicine with the prepared ethanol solution with a concentration of 65% for 36 hours, adding the soaked Chinese medicine mixture into a percolation barrel in batches, and lightly pressing and flattening; adding the prepared ethanol solution with a concentration of 65% into the percolation barrel until it exceeds the surface of the medicinal material by 1-2 cm, soaking for 18 hours, percolating the remaining ethanol, and retaining the medicinal residue for standby; decompressing and concentrating the obtained alcohol solution, and drying to obtain a Chinese medicine composite powder A; adding water 5 times the amount of the medicinal residue to the medicinal residue, decocting and extracting for 1-2 hours (optimally 1.5 hours), centrifuging, decompressing and concentrating the medicinal solution to obtain a Chinese medicine composite powder B, and evenly mixing the Chinese medicine composite powder A and the Chinese medicine composite powder B to obtain the Chinese medicine composition.
[0048] Example 5
[0049] A health-care Chinese medicine composition comprises the following raw materials in weight ratio: 8% wild chrysanthemum, 3% honeysuckle, 9% mint, 9% poria, 16.5% atractylodes, 1% cinnamon, 1% clove, 9% astragalus, 9% ganoderma lucidum, 13.5% chuanxiong, 10% costusroot and 11% liquorice.
[0050] The preparation method of the traditional Chinese medicine composition comprises: weighing chuanxiong, atractylodes, costusroot, clove, cinnamon bark and mint according to the weight ratio, adding an appropriate amount of volatile oil extraction solvent to extract volatile oil, wherein the amount of volatile oil extraction solvent used is 4 times the amount of water of the medicinal materials, and the extraction time is 2-12 hours (optimally 10 hours); after the volatile oil is extracted, cyclodextrin inclusion is carried out at a temperature below 40°C, and the inclusion time is 5 hours; filtering the decoction and collecting it in another device as a filtrate for standby use; mixing the residue obtained after the volatile oil extraction with 10-15 times (optimally 12 times) of tuckahoe, astragalus, wild chrysanthemum, ganoderma lucidum, honeysuckle and liquorice weighed according to the weight ratio; The method comprises the following steps: decocting the medicinal material in water for 2-5 times (optimally 3 times), each time for 1-2 hours (optimally 1.5 hours); filtering the decoction obtained by decoction, combining the filtered medicinal solution with the filtrate obtained after extracting volatile oil to obtain a mixed Chinese medicine liquid; concentrating the obtained mixed Chinese medicine liquid by water bathing to a clear paste with a relative density of 1.06-1.08, adding ethanol to make the alcohol content reach 60%, and standing for more than 12 hours (optimally 24 hours) to obtain a mixed Chinese medicine alcohol liquid; concentrating the mixed Chinese medicine alcohol liquid under reduced pressure, drying, and adding a volatile oil cyclodextrin inclusion compound to obtain a Chinese medicine composition.
[0051] Pharmacodynamics test:
[0052] In order to verify the effect of the present invention in tumor treatment, the Chinese medicine composition prepared by the method of Example 1 was used in the following efficacy test.
[0053] 1 Test materials
[0054] 1.1 The test drugs include a Chinese medicine composition containing Sophora flavescens (hereinafter referred to as the original prescription) and a Chinese medicine composition prepared by the method of Example 1 (hereinafter referred to as the present prescription). Properties: black-brown viscous liquid. Usage and dosage: oral administration. The clinical recommended dose of the original prescription is 7.6g crude drug / 60kg / d, and the clinical recommended dose of the present prescription is 7.0g crude drug / 60kg / d. Sample drug content: 1g crude drug / ml. Storage conditions: refrigerated. Note: Warm the drug solution to 35-40°C and shake well before use.
[0055] 1.2 Positive control drug Cyclophosphamide for injection, manufacturer: Jiangsu Shengdi Pharmaceutical Co., Ltd. Indications: This product is a widely used anticancer drug, which has a good effect on malignant lymphoma, acute or chronic lymphocytic leukemia, multiple myeloma, and has a certain effect on lung cancer and breast cancer. Batch number: 17020625, production date: 2017.02.06, valid until: 2019.02.05. Ingredients: Cyclophosphamide. Properties: white crystals or crystalline powder. Specifications: 0.2g / bottle, 10 bottles / box. Usage and dosage: For intravenous injection in adults, 500-1000mg / m2 each time according to body surface area, once a week, for 2 consecutive times, rest for 1-2 weeks and repeat. Storage conditions: light-shielded, sealed, stored below 30°C.
[0056] 1.3 Experimental animals
[0057]
[0058]
[0059] 1.4 Tumor cell lines
[0060]
[0061] 1.5 Test reagents
[0062]
[0063] 1.6 Test equipment
[0064]
[0065]
[0066] 1.7 Main consumables for the test
[0067]
[0068]
[0069] 2 Test methods
[0070] 2.1 Dosage design
[0071] 2.1.1 Original formula: The recommended clinical dose for adults is 7.6g crude drug / 60kg / d. In the experiment, the unit dose for mice is 11 times that for humans based on the body surface area of humans and animals. The dosage for mice is (7.6 / 60)×11=1.4g crude drug / kg / d. The concentration of the drug solution submitted for testing is 1g crude drug / ml. The dosage for mice is converted into a volume of 1.4 / 1=1.4ml / kg / d. Therefore, the high and low doses of the original formula are 2.8ml / kg / d and 1.4ml / kg / d (equivalent to 2 times and the same times of the clinical dosage for humans, respectively).
[0072] This prescription: The recommended clinical dose for adults is 7.0g crude drug / 60kg / d. In the experiment, the unit dose for mice was 11 times that of humans based on the body surface area conversion between humans and animals. The dose for mice was (7.0 / 60)×11=1.3g crude drug / kg / d. The concentration of the drug solution submitted for inspection was 1g crude drug / ml. The dose for mice converted into a volume of 1.3 / 1=1.3ml / kg / d. Therefore, the high and low doses of this prescription are 2.6ml / kg / d and 1.3ml / kg / d (equivalent to twice and equal times the clinical dose for humans, respectively).
[0073] 2.1.2 Cyclophosphamide for injection: The recommended clinical dose for adults is 1000 mg / m 2 / time, the body surface area of an adult is 1.6246m 2 / 60kg, the converted adult clinical recommended dose is 1624.6mg / 60kg; in the experiment, the body surface area of humans and animals was converted, and the unit dose for mice was calculated as 11 times the human unit dose. The dosage for mice was (1624.6 / 60)×11=297.84mg / kg / time=0.3g / kg / time.
[0074] 2.2 Culture of human lung adenocarcinoma cell line (A549) Cell lines were cultured in complete medium (DMEM medium + 10% fetal bovine serum, pH 7.2) at 37°C and 5% CO 2 In a constant temperature incubator, the culture medium was replaced every day, and the cells were cultured to 80%-90% fusion rate, digested with 0.25% trypsin, and passaged after centrifugation. When the cells were cultured to a certain number, they were diluted with PBS to form a tumor cell suspension and inoculated into the test animals.
[0075] 2.3 Construction of A549 tumor-bearing nude mice
[0076] 1) Construction of primary A549 tumor-bearing nude mice: A549 cell line was digested with trypsin-EDTA and centrifuged at 1000 rpm. The supernatant was discarded and resuspended in DMEM high-glucose medium to make the cell concentration reach 106-107 cells / ml; 3 BALB / c nude mice were subcutaneously inoculated with 0.4 ml of A549 cell suspension in the right axilla of each mouse. The inoculated nude mice were raised normally and the living status of the nude mice and the tumor growth status were observed;
[0077] 2) Construction of passaged A549 tumor-bearing nude mice: When the tumor of the primary tumor-bearing nude mice grows to a diameter of about 1 cm, take one nude mouse with good living condition and intact tumor, peel off the tumor under sterile conditions and put it into a glass homogenizer, add 1.5 ml of sterile saline to prepare a homogenate, and then filter the homogenate with a 70 μm cell sieve, and retain the filtered homogenate; three BALB / c nude mice, each of which was subcutaneously inoculated with 0.4 ml of the homogenate in the right axilla, and the inoculated nude mice were raised normally, and the living condition of the nude mice and the tumor growth status were observed.
[0078] 2.4 Preparation of human lung cancer xenograft model
[0079] 88 nude mice weighing 18-20g were taken, half male and half female, and were adaptively raised in the experimental animal center for 5 days. When the tumor of the tumor-bearing nude mice grew to a diameter of about 1.5cm, 3 nude mice with good living conditions and intact tumors were taken, the tumors were peeled off under sterile conditions, 3.0g was weighed and put into a glass homogenizer, 20ml of sterile physiological saline was added to prepare a homogenate, and then the homogenate was filtered with a 70μm cell sieve, and the filtered homogenate was retained; 8 nude mice were randomly selected as blank control groups, and 0.2ml of homogenate was inoculated subcutaneously in the right armpit of the remaining 80 nude mice. After inoculation, they were randomly divided into 10 groups according to body weight, namely: model control group, cyclophosphamide group (0.3g / kg), The original high-dose group (2.8g / kg), the original low-dose group (1.4g / kg), the high-dose group of this prescription (2.6g / kg), the low-dose group of this prescription (1.3g / kg), cyclophosphamide (0.3g / kg) + the original high-dose group (2.8g / kg), cyclophosphamide (0.3g / kg) + the original low-dose group (1.4g / kg), cyclophosphamide (0.3g / kg) + the high-dose group of this prescription (2.6g / kg), cyclophosphamide (0.3g / kg) + the low-dose group of this prescription (1.3g / kg), 8 rats in each group.
[0080] 2.5 Administration The drug was administered on the second day after inoculation, with an intragastric administration of 0.2 ml / 10 g. The blank control group and the model control group were given distilled water under the same conditions. Cyclophosphamide was administered when the tumor grew to about 50 mm. 3 Start medication at 5:00 pm, intraperitoneal injection of 0.1 ml / 10 g.
[0081] 2.6 Sampling The mice were fasted on the night of the last administration. The body weight was measured the next morning, and the longest and shortest diameters of the tumor were measured. The eyeballs of the mice were then removed to take whole blood (anticoagulant) and serum. The tumor mass, liver, heart, spleen, lung, and kidney were removed and weighed in the order of liver, heart, spleen, lung, kidney, and tumor mass.
[0082] 2.7 Observation indicators
[0083] 1) Body weight: Weigh the body weight once a week and adjust the dosage accordingly;
[0084] 2) Tumor volume: When tumor growth can be seen, the longest diameter (a) and shortest diameter (b) of the tumor are measured with a digital vernier caliper, and the tumor volume is calculated. The calculation formula of tumor volume (TV) is: TV = (1 / 2) ab2. Measure twice a week.
[0085] 3) Tumor inhibition rate and organ index: The tumor mass, liver, heart, spleen, lung, and kidney were removed and weighed in the order of liver, heart, spleen, lung, kidney, and tumor mass, and the tumor inhibition rate and organ index were calculated:
[0086]
[0087]
[0088] Detection of blood picture indexes: Whole blood is subjected to blood cell detection, and serum is detected for glutamic pyruvic transaminase (GLT), glutamic oxaloacetic transaminase (GST), total bilirubin (TBil), total protein (TP), blood urea nitrogen (BUN), creatinine (Cre), and uric acid (UA).
[0089] 2.8 Evaluation of the combined drug effect uses the King formula, q = E(a + b) / (Ea + Eb - Ea×Eb), to evaluate whether cyclophosphamide combined with this formula or the original formula has a synergistic or antagonistic effect. Among them, E(a + b) is the effective rate of the combined drug, and Ea and Eb are the effective rates of the individual drugs; when q < 0.85, the two drugs are antagonistic, when q > 1.15, the two drugs are synergistic, and when 0.85 < q < 1.15, the effects of the two drugs are simply additive.
[0090] 2.9 Statistical analysis All data are expressed as mean ± standard deviation and the results are compared using the T-test. A p < 0.05 is considered to indicate a statistically significant difference.
[0091] 3 Experimental results
[0092] 3.1 Effects on the tumor volume growth of the nude mouse model of human lung adenocarcinoma cell line (A549)
[0093] Table 1 Results and Figure 1 and Figure 2 show that after inoculating nude mice with human lung adenocarcinoma (A549) and starting prophylactic administration on the 2nd day, from the 27th day of administration (the first measurement) to the 50th day of administration, the low-dose and high-dose groups of this formula had a significant inhibitory effect on the tumor growth of A-549 tumor-bearing nude mice, with significant differences compared with the model control group (p < 0.05, p < 0.01). Among them, the tumor inhibition rate of the high-dose group was 90.62%.
[0094] After the original formula and this formula were respectively combined with cyclophosphamide and the q value was calculated by the King formula, it showed that the therapeutic effect of cyclophosphamide combined with the low-dose of this formula on A549 tumors was the simple addition of the two drugs (q = 0.97); the therapeutic effects of cyclophosphamide combined with the low-dose of the original formula (q = 0.27), cyclophosphamide combined with the high-dose of the original formula (q = 0.34), and cyclophosphamide combined with the high-dose of this formula (q = -3.47) on A549 tumors were all antagonistic to each other.
[0095] Neither the low-dose and high-dose groups of the original formula alone nor their combination with cyclophosphamide showed a preventive effect on the occurrence of human lung adenocarcinoma.
[0096] Figure 3 、 Figure 4and Figure 5 The results showed that during the drug administration period, the body weight of mice in the low- and high-dose groups of the original prescription and the low- and high-dose groups of this prescription increased significantly compared with the model control group; and after combined administration with phosphoramide, the body weight of each group decreased significantly after 4 weeks of administration.
[0097]
[0098]
[0099]
[0100] In the above tables and drawings in the specification, the one without Sophora flavescens is this one.
[0101] 3.2 Effects on liver function of nude mice bearing human lung adenocarcinoma cell line (A549)
[0102] The results in Table 2 show that there were no significant changes in liver index, serum ALT, serum AST, ALT / AST, serum TBil, and serum TP levels in the model control group, cyclophosphamide group, and each drug-treated group.
[0103]
[0104]
[0105]
[0106] 3.3 Effects on renal function of nude mice bearing human lung adenocarcinoma cell line (A549)
[0107] The results in Table 3 show that there were no significant changes in renal index, serum BUN, serum UA and serum CRE levels in the model control group, cyclophosphamide group and each drug-treated group.
[0108]
[0109]
[0110] 3.4 Effects on the heart, spleen and lung indexes of nude mice with human lung adenocarcinoma cell line (A549) The results in Table 4 show that: ① Heart index: Compared with the blank control group, the heart index of the model control group tended to increase; the heart index of the high-dose original prescription, the low-dose and high-dose of this prescription, and the cyclophosphamide + low-dose and high-dose groups of the original prescription were significantly reduced, and there were significant differences compared with the model control group and the cyclophosphamide group (p<0.05, p<0.01). ② The spleen index and lung index of the model control group, the cyclophosphamide group and each drug-treated group were not statistically significant.
[0111]
[0112]
[0113] 3.5 Effects on blood routine test of nude mice bearing human lung adenocarcinoma cell line (A549)
[0114] The results in Table 5 show that the total number of white blood cells, neutrophils, lymphocytes and monocytes in the model control group was significantly reduced, and there was a significant difference compared with the blank control group (p<0.05, p<0.01);
[0115] The numbers of white blood cells, neutrophils, lymphocytes and monocytes were increased in the high-dose group of the original prescription, the low-dose group and the high-dose group of this prescription when the drugs were used alone, and in combination with cyclophosphamide and the low-dose group and the high-dose group of the original prescription, and the low-dose group and the high-dose group of this prescription, which were significantly different from those in the model control group (p<0.05, p<0.01).
[0116] After the high-dose group of the original prescription and the low-dose group of this prescription were used in combination with cyclophosphamide, the effect of increasing the number of white blood cells, neutrophils, lymphocytes and monocytes was better than that of each drug used alone, and there was a significant difference compared with the cyclophosphamide control group (p<0.05, p<0.01).
[0117] The basophils in the model control group increased significantly; the basophils in the cyclophosphamide group, this prescription and the original prescription alone, and in combination with cyclophosphamide, all increased significantly.
[0118] The levels of red blood cells, platelets, hemoglobin and eosinophils in the normal control group, model control group and each drug-treated group were all within the normal range.
[0119]
[0120]
[0121]
[0122] 4 Conclusion
[0123] 1) Low and high doses of this prescription alone had a significant preventive effect on tumor growth in A-549 tumor-bearing nude mice, with the high dose tumor inhibition rate being 90.62%.
[0124] 2) The low dose of this prescription combined with cyclophosphamide has a simple additive effect on the treatment of A549 tumors (q=0.97).
[0125] 3) Low and high doses of the original formula as well as low and high doses of this formula alone significantly increased the body weight of tumor model mice.
[0126] 4) High doses of the original prescription, low and high doses of this prescription alone, and low and high doses of the original prescription combined with cyclophosphamide can significantly reduce the cardiac index.
[0127] 5) The number of white blood cells, neutrophils, lymphocytes and monocytes can be increased after high doses of the original prescription, low and high doses of this prescription are used alone, and low and high doses of the original prescription, low and high doses of this prescription are used in combination with cyclophosphamide.
[0128] 6) The high dose of the original prescription, the low dose of this prescription and cyclophosphamide combined with the effect of increasing the number of white blood cells, neutrophils, lymphocytes and monocytes is better than the single drug
[0129] 7) Both the original prescription and this prescription alone or in combination with cyclophosphamide can significantly increase the basophils.
[0130] 8) There were no significant changes in liver index, kidney index, spleen index, lung index, serum BUN, serum UA, and serum CRE levels in each medication group when using the drug alone or in combination. There were no significant effects on serum ALT, serum AST, ALT / AST, serum TBil, and serum TP levels.
[0131] 9) The levels of red blood cells, platelets, hemoglobin and eosinophils in each medication group after single or combined medication were all within the normal range.
[0132] The prescription of the Chinese medicine composition of the present invention is explained as follows:
[0133] Element:
[0134] Ganoderma lucidum (sessile Ganoderma lucidum and pine needle pore fungus) Astragalus
[0135] Atractylodes lancea, licorice, cinnamon, costusroot, poria, cloves
[0136] Honeysuckle and wild chrysanthemum
[0137] Mint Chuanxiong
[0138] Jun: Lingzhi (sessile Lingzhi and Pine Needle Foliar) Astragalus
[0139] Minister: Atractylodes, licorice, cinnamon, costusroot, tuckahoe, cloves
[0140] Accompanying: Honeysuckle and wild chrysanthemum
[0141] Made with: Chuanxiong and Mint
[0142] Indications: Tumor patients with spleen and lung qi deficiency, qi and blood stasis, phlegm and dampness, and low immunity.
[0143] Function: Strengthen the spleen and lungs, disperse stagnation and eliminate accumulation, increase white blood cells, neutrophils, lymphocytes and other immune cells, and enhance immunity.
[0144] Analysis: Ganoderma lucidum nourishes the five internal organs, strengthens the spleen and replenishes qi, and improves the body's immunity; Astragalus strengthens the spleen and replenishes lungs, replenishes qi and raises yang, and improves the body's immunity; Ganoderma lucidum and Astragalus can inhibit the growth of tumor telomerase; Atractylodes, Poria, and Licorice strengthen the spleen and eliminate dampness; Cinnamon, Costus root, and Clove are pungent and warm, regulating qi, warming the middle, dispersing cold and relieving pain; Honeysuckle clears heat and detoxifies; Wild chrysanthemum clears the liver, improves eyesight and detoxifies; Peppermint is pungent and cool, detoxifies, soothes the liver and relieves depression; Chuanxiong regulates qi, promotes blood circulation and relieves pain.
[0145] This prescription uses Ganoderma lucidum and Astragalus membranaceus to strengthen the spleen and replenish qi, nourish the five internal organs, strengthen the body and fight tumors as the main medicines; Atractylodes lancea, Poria cocos, and Licorice root to strengthen the spleen and eliminate dampness; Cinnamon bark, costus root, and cloves to regulate qi and warm the middle, dispel cold and relieve pain as assistant medicines; Wild chrysanthemum and honeysuckle are adjuvant medicines to clear heat and detoxify; Chuanxiong and mint are guiding medicines to clear the liver, promote blood circulation and relieve pain.
[0146] The above is only used to illustrate the technical solution of the present invention rather than to limit it. Other modifications or equivalent substitutions made to the technical solution of the present invention by ordinary technicians in this field should be included in the scope of the claims of the present invention as long as they do not depart from the spirit and scope of the technical solution of the present invention.
Claims
1. A Chinese medicine composition for treating lung tumors, characterized in that: The traditional Chinese medicine composition for treating lung tumors is prepared from the following raw materials in weight proportion: 5%-15% wild chrysanthemum, 2%-12% honeysuckle, 5%-15% mint, 5%-15% poria, 10%-20% atractylodes, 0.5%-3% cinnamon, 0.5%-3% clove, 3%-12% astragalus, 5%-15% ganoderma lucidum, 10%-20% ligusticum, 5%-12% costusroot, and 2%-10% liquorice.
2. The Chinese medicine composition for treating lung tumors according to claim 1, characterized in that: The traditional Chinese medicine composition for treating lung tumors is prepared from the following raw materials in weight proportion: 5%-10% wild chrysanthemum, 3%-8% honeysuckle, 5%-10% mint, 5%-10% poria, 12%-20% atractylodes, 0.5%-3% cinnamon, 0.5%-3% clove, 5%-10% astragalus, 5%-10% ganoderma lucidum, 11%-15% ligusticum chuanxiong, 8%-12% costusroot, and 3%-8% liquorice.
3. The Chinese medicine composition for treating lung tumors according to claim 1, characterized in that: The traditional Chinese medicine composition for treating lung tumors is prepared from the following raw materials in weight proportion: 6%-9% wild chrysanthemum, 3%-6% honeysuckle, 6%-9% mint, 6%-9% poria, 15%-18% atractylodes, 1%-3% cinnamon, 0.5%-1.5% clove, 6%-10% astragalus, 6%-10% ganoderma lucidum, 12%-15% ligusticum chuanxiong, 8%-11% costusroot, and 3%-6% liquorice.
4. The Chinese medicine composition for treating lung tumors according to any one of claims 1 to 3, characterized in that: The dosage form of the Chinese medicine composition for treating lung tumors is injection, honey-refined pills, hydrated pills, capsules, tablets, dripping pills, powders, oral liquid medicines, gels, extracts or films.
5. The method for preparing the Chinese medicine composition for treating lung tumors according to any one of claims 1 to 3, characterized in that: The preparation method comprises the following steps: Step (1) weighing each Chinese medicinal ingredient according to the weight ratio, crushing them to a particle size of 10-100 mesh, sieving them, and mixing them evenly; Step (2) preparing an ethanol solution with a concentration of 40%-95% for standby use; soaking the mixed Chinese medicine with the prepared ethanol solution with a concentration of 40%-95% for 10-48 hours, adding the soaked Chinese medicine mixture into a percolation bucket in batches, and lightly pressing and flattening; Step (3) adding the prepared 40%-95% ethanol solution to the percolation barrel in step (2) until it exceeds the surface of the medicinal material by 1-2 cm, and after soaking for a preset time, percolating the remaining ethanol, and retaining the medicinal residue for later use; the obtained alcohol solution is concentrated under reduced pressure, and dried to obtain the Chinese medicine composite powder A; Step (4) adding 2-10 times the amount of water to the medicinal residue, decocting and extracting for 0.5-2h, centrifuging and filtering, decompressing and concentrating the medicinal solution and drying to obtain a Chinese medicine composite powder B, and uniformly mixing the Chinese medicine composite powder A and the Chinese medicine composite powder B to obtain a Chinese medicine composition.
6. The method for preparing the Chinese medicine composition for treating lung tumors according to claim 5, characterized in that: In step (1), various medicinal materials are crushed to a particle size of 20-40 mesh; and the concentration of the prepared ethanol in steps (2) and (3) is 60%-80%.
7. The method for preparing the Chinese medicine composition for treating lung tumors according to claim 6, characterized in that: In the step (2), the uniformly mixed Chinese medicine is soaked for 18-30 hours; and in the step (3), the soaking time is 2-48 hours.
8. A method for preparing a traditional Chinese medicine composition for treating lung tumors according to any one of claims 1 to 3, characterized in that: The preparation method comprises the following steps: Step (1) according to the weight ratio, weigh Chuanxiong, Atractylodes, Aucklandia, Clove, Cinnamon, and Menthol, add appropriate amount of water to extract volatile oil, add cyclodextrin for inclusion, filter the decoction and collect it in another device as the remaining medicinal liquid for standby use; Step (2) boiling the residue obtained after the volatile oil is extracted and the tuckahoe, astragalus, wild chrysanthemum, ganoderma lucidum, honeysuckle and liquorice weighed according to the weight ratio in water, filtering the liquid medicine, and combining the filtered liquid medicine with the remaining liquid medicine obtained after the volatile oil is extracted to obtain a mixed Chinese medicine liquid medicine; Step (3) concentrating the obtained Chinese medicine mixed liquid into a clear paste by water bath, precipitating with alcohol, and adding ethanol to make the alcohol content reach 50%-80% to obtain a Chinese medicine mixed alcohol liquid; Step (4) concentrates the Chinese medicine mixed alcohol solution under reduced pressure, and after drying, adds volatile oil cyclodextrin inclusion compound to prepare a Chinese medicine composition.
9. The method for preparing the Chinese medicine composition for treating lung tumors according to claim 8, characterized in that: In the step (1), the amount of volatile oil extraction solvent is 4-15 times the amount of water of the medicinal material, and the extraction time is 2-12 hours; the obtained volatile oil is subjected to cyclodextrin inclusion at below 40 degrees Celsius, and the inclusion time is 1-10 hours.
10. A use of a Chinese medicine composition, characterized in that: The Chinese medicine composition is used in combination with cyclophosphamide for the treatment of lung tumors. The Chinese medicine composition is the Chinese medicine composition for the treatment of lung tumors according to any one of claims 1 to 3.
Citation Information
Patent Citations
Traditional Chinese medicine composition used for treating tumors and preparation method thereof
CN108567820A
Traditional chinese medicine composition for treating tumours, preparation method therefor and use thereof
TW202041228A
